HIV News and Research

RSS

Research may offer potent vaccines for viruses such as HIV and West Nile

Researchers at La Jolla Institute for Allergy & Immunology (LIAI) have identified two molecules (TL and CD8aa) that cooperate to trigger immune cells to develop into long-lived memory cells to fight recurring infections. This finding may have important implications for the future development of longer lasting and more potent vaccines for viruses such as HIV and West Nile.

23 Apr 2004

Public-health experts caution that the widening of the EU could have adverse effects on public health

Public-health experts writing in this week's issue of THE LANCET caution that the widening of the European Union (EU) to the east could have potentially adverse effects on public health-both for the new member countries, many of whom have poor health-care infrastructure, and for existing EU members.

23 Apr 2004

WHO renews call for effective malaria treatment

More than 600 million people, most of them children living in sub-Saharan Africa, face the daily threat of death from malaria because new, effective treatments are not available where they live. Existing, cheaper medicines, which have been used for many years, are no longer effective in most places because the malaria parasite has developed resistance to them.

22 Apr 2004

No relationship between HIV and oral polio vaccine

HIV-AIDS did not come from oral polio vaccine contaminated with chimpanzee virus, reports a research team led by a University of Arizona evolutionary biologist

21 Apr 2004

Can public health promotion beat disease?

Huge efforts are under way to address health problems such as SARS, HIV, diabetes and many other illnesses by developing vaccines or therapeutic drugs.

20 Apr 2004

Jefferson scientists learn how HIV causes dementia

Ever since the AIDS epidemic began more than two decades ago, scientists have been trying to understand why as many as one-quarter of those infected with HIV develop dementia.

19 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Three actors tested positive for HIV - Quarantine list update

The US pornographic film industry is in turmoil from a two-month production shutdown after three actors tested positive for HIV.

17 Apr 2004

AIDS advocates and patients protest Abbott Laboratories' Norvir price hikes

A broad coalition of AIDS advocates and patients will come together in protest over Abbott Laboratories' recent unprecedented 400% price hike on Norvir (ritonavir), their key AIDS drug.

16 Apr 2004

$360,000 boost for HIV/AIDS patients in Pima County

The University of Arizona has been awarded $360,000 from the federal Ryan White CARE Act to expand its patient care services for HIV/AIDS patients in Pima County. Ryan White Early Intervention Services Clinics now are held at the University of Arizona Health Sciences Center and at Kino Hospital.

16 Apr 2004

New centre for AIDS research opens in Southampton UK

International experts on HIV/AIDS were in Southampton today (Thursday 15 April) to mark the official opening of a new Centre for AIDS Research at the city's University.

16 Apr 2004

New forensic tool to detect infectious diseases

Tests for the detection of infectious diseases in North Queensland will be faster and cheaper, thanks to the purchase of new equipment in James Cook University's School of Biomedical Sciences.

16 Apr 2004

HIV Vaccine Program to Lead Local Efforts

May 18 has been designated HIV Vaccine Awareness Day, a day to educate Americans about the need for a vaccine to prevent HIV. This year's theme is "Real People. Real Progress." Thousands of study volunteers, scientists, and health care professionals are committed to finding a safe and effective vaccine.

15 Apr 2004

Health Canada funds HIV/AIDS project

In Canada, it is estimated that every day one Aboriginal person becomes infected with HIV/AIDS. Partners in this project include le Centre de Santé Vallée-de-l'Or, la Régie Régionale de la santé et des services sociaux de l'Abitibi-Témiscamingue, le Service de Santé Kitcisasik, le Service de Santé Lac Simon, La clinique régionale VIH/sida and staff from MRC de la Vallée-de-l'Or.

14 Apr 2004

21st century is shaping up to be the "century of vaccines"

The 21st century is shaping up to be the "century of vaccines," as vaccine developers make striking progress against both emerging and longstanding diseases, according to Vaccines: Preventing Diseases and Protecting Health, from the Pan American Health Organization (PAHO).

14 Apr 2004

FUZEON (enfuvirtide) to be widely available through pharmacies in the U.S.

Roche and Trimeris today announced that FUZEON(R) (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV, will now be available through retail and specialty pharmacies across the U.S. beginning on April 26.

13 Apr 2004

Protein sequences harder to predict than originally thought

Scientists have believed for decades that the sequencing of the human genome would automatically yield the sequences of proteins, the functional products of genes, and thus lead to the unraveling of the mechanisms behind human cell biology and disease.

12 Apr 2004

New research into Human Papilloma Virus (HPV) and Cervical Cancer

Cervical cancer is the second-most prevalent cancer in women and, despite encouraging improvements in screening leading to earlier detection, cervical cancer still kills many women every year. The risk of cervical cancer is increased by infection with certain types of human papilloma virus (HPV).

12 Apr 2004

China steps up fight against AIDS

China will increase medical aid and offer free education to hundreds of children orphaned by AIDS in a central province ravaged by the deadly disease.

11 Apr 2004

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

9 Apr 2004